Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfentanil as an adjuvant for ciprofol, remimazolam, and propofol-based hysteroscopic sedation
ChiCTR2300067310Phase 4Not yet recruiting
- Sponsor
- Department of Anesthesia Surgery, Gansu Provincial People's Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in pelvic pain comparing Alfentanil + ciprofol, Alfentanil + remimazolam and Alfentanil + propofol (3 arms). Primary endpoints: Incidence of intraoperative adverse events and Duration of patient's full consciousness. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
alfentanilciprofolremimazolampropofol
03
Conditions
pelvic pain
Beyond the preview
Go deeper on ChiCTR2300067310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067310.